Inventor · disambiguated record
Jun Feng
Also filed as: FENG JUN
92 granted patents·35 pending applications·1,107 citations·filing 1998–2025
99Inventor score
Files withARAXES PHARMA LLC52TAKEDA PHARMACEUTICAL12JIANGSU HENGRUI MEDICINE CO9KURA ONCOLOGY INC9FENG JUN8
Top patents by PatentIndex Score
127 records- 0198US10144724B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Dec 4, 2018·44 cites·42 claims
- 0297US10745385B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2018·Granted Aug 18, 2020·17 cites·54 claims
- 0397US10377743B2Inhibitors of RAS and methods of use thereofARAXES PHARMA LLC·Filed 2017·Granted Aug 13, 2019·29 cites·31 claims
- 0497US10370386B2Substituted quinolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2017·Granted Aug 6, 2019·33 cites·30 claims
- 0597US10351550B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 16, 2019·27 cites·32 claims
- 0697US10246424B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Apr 2, 2019·36 cites·90 claims
- 0797US9926267B2Covalent inhibitors of K-Ras G12CARAXES PHARMA LLC·Filed 2015·Granted Mar 27, 2018·38 cites·35 claims
- 0897US9862701B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2015·Granted Jan 9, 2018·45 cites·18 claims
- 0997US9840516B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2014·Granted Dec 12, 2017·73 cites·33 claims
- 1097US9745319B2Irreversible covalent inhibitors of the GTPase K-Ras G12CARAXES PHARMA LLC·Filed 2014·Granted Aug 29, 2017·43 cites·11 claims
- 1197US9227978B2Covalent inhibitors of Kras G12CARAXES PHARMA LLC·Filed 2014·Granted Jan 5, 2016·47 cites·24 claims
- 1296US10927125B2Substituted cinnolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 23, 2021·11 cites·29 claims
- 1396US10919850B2Covalent inhibitors of KRas G12CARAXES PHARMA LLC·Filed 2019·Granted Feb 16, 2021·9 cites·38 claims
- 1496US10858343B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 8, 2020·11 cites·15 claims
- 1596US10829458B2Substituted quinazoline compounds and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Nov 10, 2020·13 cites·29 claims
- 1696US10730867B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Aug 4, 2020·15 cites·19 claims
- 1796US10723738B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2019·Granted Jul 28, 2020·15 cites·22 claims
- 1896US10689356B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jun 23, 2020·16 cites·15 claims
- 1996US10414757B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Sep 17, 2019·33 cites·49 claims
- 2096US10280172B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2017·Granted May 7, 2019·34 cites·19 claims
- 2196US10273207B2Covalent inhibitors of kras G12CARAXES PHARMA LLC·Filed 2018·Granted Apr 30, 2019·24 cites·34 claims
- 2296US10077271B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2017·Granted Sep 18, 2018·14 cites·18 claims
- 2395US10736897B2Compounds and methods of use thereof for treatment of cancerARAXES PHARMA LLC·Filed 2018·Granted Aug 11, 2020·28 cites·15 claims
- 2495US10428064B2Fused-tricyclic inhibitors of KRAS and methods of use thereofARAXES PHARMA LLC·Filed 2016·Granted Oct 1, 2019·27 cites·28 claims
- 2595US10011600B2Methods and compositions for inhibition of RasARAXES PHARMA LLC·Filed 2015·Granted Jul 3, 2018·12 cites·21 claims
- 2694US11878985B2Substituted quinazolines as inhibitors of KRAS G12CARAXES PHARMA LLC·Filed 2020·Granted Jan 23, 2024·2 cites·43 claims
- 2794US11377441B2Covalent inhibitors of KRASARAXES PHARMA LLC·Filed 2020·Granted Jul 5, 2022·3 cites·28 claims
- 2894US11021470B22-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereofARAXES PHARMA LLC·Filed 2019·Granted Jun 1, 2021·8 cites·21 claims
- 2994US10882847B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Jan 5, 2021·11 cites·23 claims
- 3094US10875842B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Dec 29, 2020·11 cites·20 claims
- 3194US8871774B2Inhibitors of influenza viruses replicationVERTEX PHARMA·Filed 2013·Granted Oct 28, 2014·18 cites·29 claims
- 3294US7781584B2Dipeptidyl peptidase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2007·Granted Aug 24, 2010·17 cites·4 claims
- 3393US11059819B2Fused hetero-hetero bicyclic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jul 13, 2021·8 cites·20 claims
- 3493US10975071B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted Apr 13, 2021·9 cites·20 claims
- 3593US10822312B2Substituted quinazoline compounds and methods of useARAXES PHARMA LLC·Filed 2017·Granted Nov 3, 2020·10 cites·12 claims
- 3693US10647703B2Inhibitors of KRAS G12C mutant proteinsARAXES PHARMA LLC·Filed 2016·Granted May 12, 2020·18 cites·13 claims
- 3793US9434743B2Indazole derivativesTAKEDA PHARMACEUTICALS CO·Filed 2013·Granted Sep 6, 2016·20 cites·18 claims
- 3892US10588907B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2016·Granted Mar 17, 2020·6 cites·1 claims
- 3992US10174041B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 8, 2019·11 cites·24 claims
- 4090US11964971B2Methods and compositions for modulating splicingSKYHAWK THERAPEUTICS INC·Filed 2021·Granted Apr 23, 2024·2 cites·20 claims
- 4190US7795428B2Dipeptidyl peptidase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2007·Granted Sep 14, 2010·12 cites·59 claims
- 4289US11279689B21-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancerARAXES PHARMA LLC·Filed 2018·Granted Mar 22, 2022·4 cites·13 claims
- 4389US11136308B2Substituted quinazoline and quinazolinone compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Oct 5, 2021·5 cites·26 claims
- 4489US10246464B2Thienopyrimidine and thienopyridine compounds and methods of use thereofUNIV MICHIGAN REGENTS·Filed 2015·Granted Apr 2, 2019·9 cites·20 claims
- 4588US11542248B2Methods and compositions for inhibiting the interaction of menin with MLL proteinsKURA ONCOLOGY INC·Filed 2018·Granted Jan 3, 2023·4 cites·14 claims
- 4688US11274093B2Fused bicyclic benzoheteroaromatic compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Mar 15, 2022·4 cites·16 claims
- 4788US7470700B2Dipeptidyl peptidase inhibitorsTAKEDA PHARMACEUTICAL·Filed 2004·Granted Dec 30, 2008·23 cites·31 claims
- 4888US2024352028A1Substituted quinazolines as inhibitors of kras g12cARAXES PHARMA LLC·Filed 2024·Application pending·0 cites
- 4987US11358959B2Benzothiophene and benzothiazole compounds and methods of use thereofARAXES PHARMA LLC·Filed 2018·Granted Jun 14, 2022·4 cites·20 claims
- 5087US9624228B2Inhibitors of ERK and methods of useKURA ONCOLOGY INC·Filed 2014·Granted Apr 18, 2017·3 cites·17 claims
Showing the top 50 of 127 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jun Feng files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →